Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.5.4.4 (adenosine deaminase)
 5,136 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Adenosine is known to induce rapid cardioplegic arrest and to improve postischemic recovery in the isolated rat heart. Long exposures to high doses of adenosine impair postischemic recovery, however. In this paper we tested the combination of low-dose adenosine (1 mmol/L) with potassium (26 mmol/L), with the aim of achieving rapid arrest (as with high-dose adenosine) but eliminating the need for postarrest washout of adenosine. Cardioplegic solutions studied were (1) Krebs-Henseleit potassium (26 mmol/L) (K); (2) K plus adenosine (1 mmol/L) (KA); (3) K plus an adenosine deaminase inhibitor [erythro-9-(2-hydroxy-3-nonyl)adenine] (0.1 mmol/L) (KE); and as control (4) Krebs-Henseleit potassium (6 mmol/L) (C). We induced cardiac arrest in Langendorff-perfused rat hearts by infusing the cardioplegic solution for 3 minutes at 3 ml/min. Total ischemia lasted 20 minutes at 37 degrees C, followed by reperfusion for 30 minutes. High potassium decreased the arrest time from 260 +/- 16 seconds (group C, mean values +/- standard error of the mean) to 22 +/- 4 seconds (group K). A further decrease to 10 +/- 2 seconds was observed with KA (p = 0.016 versus K). KE, which increased endogenous adenosine, gave intermediate effects. All hearts recovered during reperfusion; the product of developed tension and heart rate (grams per minute) was superior in KA hearts (6250 +/- 740 versus K hearts 4380 +/- 390; p = 0.050). KE gave an intermediate result (5290 +/- 900), while C showed the worst recovery (3180 +/- 830). Our electrophysiologic studies with sinus node and atrial tissue suggest that adenosine induced hyperpolarization and an increase in potassium permeability, thereby arresting the sinus node before depolarization of the membrane by potassium (26 mmol/L). We conclude that low-dose adenosine as an adjunct to potassium shortens the arrest time in this model and improves postischemic recovery.
J Thorac Cardiovasc Surg 1990 Sep
PMID:Adenosine as adjunct to potassium cardioplegia: effect on function, energy metabolism, and electrophysiology. 239 80

Intracellular adenosine formation and release to extracellular space was studied in WI-L2-B and SupT1-T lymphoblasts under conditions which induce or do not induce ATP catabolism. Under induced conditions, B lymphoblasts but not T lymphoblasts, release significant amounts of adenosine, which are markedly elevated by adenosine deaminase inhibitors. In T lymphoblasts, under induced conditions, only simultaneous inhibition of both adenosine deaminase activity and adenosine kinase activities resulted in small amounts of adenosine release. Under noninduced conditions, neither B nor T lymphoblasts release adenosine, even in the presence of both adenosine deaminase or adenosine kinase inhibitors. Comparison of B and T cell's enzyme activities involved in adenosine metabolism showed similar activity of AMP deaminase, but the activities of AMP-5'-nucleotidase, adenosine kinase and adenosine deaminase differ significantly. B lymphoblasts release adenosine because of their combination of enzyme activities which produce or utilize adenosine (high AMP-5'-nucleotidase and relatively low adenosine kinase and adenosine deaminase activities). Accelerated ATP degradation in B lymphoblasts proceeds not only via AMP deamination, but also via AMP dephosphorylation into adenosine but its less efficient intracellular utilization results in the release of adenosine from these cells. In contrast, T lymphoblasts release far less adenosine, because they contain relatively low AMP-5'-nucleotidase and high adenosine kinase and adenosine deaminase activities. In T lymphoblasts, AMP formed during ATP degradation is not readily dephosphorylated to adenosine but mainly deaminated to IMP by AMP deaminase. Any adenosine formed intracellularly in T lymphoblasts is likely to be efficiently salvaged back to AMP by an active adenosine kinase. In general, these results may suggest that adenosine can be produced only by selective cells (adenosine producers) whereas other cells with enzyme combination similar to SupT1-T lymphoblasts can not produce significant amounts of adenosine even in stress conditions.
J Biol Chem 1990 Sep 15
PMID:Selective adenosine release from human B but not T lymphoid cell line. 239 45

To test whether inosine interferes with the action of adenosine, we investigated the effects of intracoronary administration of inosine, adenosine, 8-phenyltheophylline, and adenosine deaminase on isolated rat heart. Inosine did not change heart rate or developed tension but increased the effluent adenosine concentration. Inosine also decreased exogenous adenosine uptake and breakdown. After the start of the inosine infusion (20 microM), a transient 30% decrease of coronary flow took place within 0.5 min. The nucleoside caused sustained vasodilation, dependent on the concentration (30-400 microM). After the infusion we observed a transient vasodilation. A nonvasoactive inosine concentration (10 microM) combined with an adenosine concentration that increased flow by 60% (0.1 microM) raised vasodilation by another 60%. Infusion of adenosine, adenosine deaminase, or 8-phenyltheopylline did not influence the inosine-induced transient decrease of flow, suggesting that this decrease is independent of adenosine and its receptor. We conclude that inosine 1) potentiates the vasodilation induced by adenosine and 2) is a coronary vasodilator but probably also a vasoconstrictor.
Am J Physiol 1990 Sep
PMID:Inosine transiently decreases coronary flow but potentiates vasodilation by adenosine. 239 86

We tested the effect of the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenosine (EHNA) on ischemia-reperfusion injury in isolated perfused rat heart. In the ischemia-reperfusion group (n = 10), ventricular fibrillation occurred within 3 min of reperfusion after the 40-min ischemic period. The incidence of ventricular fibrillation was 90% with a mean duration of 3.15 +/- 0.97 (SE) min. Resting tension increased significantly. By contrast, the incidence of ventricular fibrillation after reperfusion in the EHNA-treated (5 microM) group (n = 10) was 20% (P less than 0.01), and the duration was 0.30 +/- 0.21 min (P less than 0.01). Resting tension was significantly lower and around the normal level in the EHNA-treated group (P less than 0.01). Contraction amplitude and heart rate recovered to nearly normal compared with the ischemia-reperfusion group (P less than 0.01). Coronary flow was greater in the EHNA-treated group (P less than 0.01). It is concluded that EHNA protects the heart, possibly by accumulation of adenosine that benefits the hearts and by blocking the xanthine oxidase pathway for free radical generation.
Am J Physiol 1990 Sep
PMID:Protective effects of an adenosine deaminase inhibitor on ischemia-reperfusion injury in isolated perfused rat heart. 239 91

To determine the mechanism(s) of transcellular adenosine transport in epithelial tissues that possess an adenosine receptor response, we studied [3H]adenosine uptake using vesicles prepared from isolated brush-border and basolateral membranes of the rabbit ileum. In the presence of the adenosine deaminase inhibitor deoxycoformycin uptake of [3H]adenosine into brush-border membrane vesicles is stimulated fivefold by an inwardly directed Na gradient. Na-dependent [3H]adenosine uptake is enhanced and concentrative under conditions that increase inside negativity of vesicles, thus providing evidence for an electrogenic carrier. Na-dependent adenosine uptake is a saturable function of adenosine concentration with a Michaelis-Menten constant of 17.3 +/- 7.1 microM and maximum transport rate of 216.9 +/- 20.2 pmol.min-1.mg protein-1. Both uridine and inosine inhibit [3H]adenosine uptake, suggesting that the Na-dependent transporter has broad substrate specificity for both purine and pyrimidine ribonucleosides. Na-dependent adenosine uptake is inhibited by dipyridamole but is insensitive to 6-(4-nitrobenzyl)thio-9-beta-D-ribofuranosylpurine. We conclude that adenosine is transported across ileal brush-border membranes by a Na-ribonucleoside cotransport system. In contrast, adenosine uptake in basolateral membranes is not stimulated by a Na gradient. These studies show asymmetry in the distribution of transport systems for adenosine in polarized intestinal epithelia.
Am J Physiol 1990 Sep
PMID:Sodium-adenosine cotransport in brush-border membranes from rabbit ileum. 239 91

9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-beta-D-arabinosyl]adeni ne (1c) and 9-[5'-(2-oxo-1,3,2-dioxaphosphorinan-2-yl)-beta-D-arabinosyl]adeni ne (1d) were synthesized by reaction of 9-[beta-D-arabinofuranosyl]adenine with phosphoryl chloride with 1-amino-3-propanol and 1,3-propanediol, respectively. 1c consisted of a mixture of diastereomers, while 1d was enantiomerically homogeneous. The structures of these compounds were established by spectral (1H NMR, MS, UV) and elemental analyses. Both 1c and 1d were resistant to degradation by 5'-nucleotidase, alkaline phosphatase, venom phosphodiesterase, crude snake venom, adenosine deaminase, and adenylate deaminase. Neither compound was significantly biotransformed by mouse hepatic microsomal preparations in the presence of an NADPH-generating system. Compound 1c was marginally effective at prolonging the life span of mice bearing P-388 leukemia; compound 1d, however, was inactive.
J Med Chem 1985 Sep
PMID:Synthesis and biological evaluation of 9-[5'-(2-oxo-1,3,2-oxazaphosphorinan-2-yl)-beta-D-arabinosyl]ade nine and 9-[5'-(2-oxo-1,3,2-dioxaphosphorinan-2-yl)-beta-D-arabinosyl]ade nine: potential neutral precursors of 9-[beta-D-arabinofuranosyl]adenine 5'-monophosphate. 241 27

In C57BL/6 mice, cytotoxic T lymphocyte (CTL) lines have previously been found to exhibit low (less than 150 U/mg) or undetectable (less than 20 U/mg) adenosine deaminase (ADA) levels (Minkowski, Castellazzi and Buttin, J. Immunol. 1984. 133: 52) in contrast to what has been seen in T helper lines (1770 +/- 340 U/mg; Minkowski and Bandeira, Cell. Immunol. 1985. 95: 380). Treatment of one of these CTL ADA- lines with the demethylating agent 5-azacytidine gave rise to an ADA+ population. Subsequent cloning allowed the recovery of pure ADA+ clones showing a rather narrow range of activity with an average value of 2030 +/- 504 U/mg. The restored ADA+ activity is stable over several months of continuous growth. It is identical to the activity of C57BL/6 thymic cells or C57BL/6 T tumor lines regarding its sensitivity to ADA inhibitors 2-deoxycoformycin and erythro-9-(2-hydroxyl-3-nonyl)adenine, and its electrophoretic mobility under nondenaturing conditions (starch gel and isoelectric focusing). An ADA-specific, 1.4-kb mRNA is present in the reactivated clones but is undetectable in the CTL ADA- parental line. These results demonstrate that the ADA- phenotype is due to an extinction of the corresponding gene. They suggest that the extinction of the ADA gene which appears to be specific for CTL and to take place in vivo during T cell differentiation may result from increased methylation in or near the ADA gene. This extinction seems to affect specifically ADA since nucleoside phosphorylase, the enzyme which follows ADA in the purine salvage pathway, is present at equivalent levels in the ADA- and ADA+ CTL clones.
Eur J Immunol 1986 Sep
PMID:Azacytidine-induced reactivation of adenosine deaminase in a murine cytotoxic T cell line. 242 25

Neurons of the tuberomammillary nucleus (TM) in the rat have previously been shown to contain the enzymes adenosine deaminase (ADA), histidine decarboxylase (HDC) and glutamate decarboxylase (GAD). Some neurons coextensive with this cell group also exhibit immunoreactivity for the neuropeptide galanin, express monoamine oxidase activity (MAO), or display the ability to accumulate and decarboxylate 5-hydroxytryptophan (5-HTP). Histochemical and immunohistochemical techniques were used to determine the extent to which these neurochemical properties are colocalized in neurons immunoreactive for adenosine deaminase. Galanin was found to coexist with ADA in about 45% of the neurons in the TM. In addition, a large number of cells immunoreactive for galanin alone were observed in the posterior hypothalamus outside the confines of TM. Neurons displaying MAO activity formed a subpopulation of those immunoreactive for ADA; all neurons containing MAO also contained ADA whereas only 60% of the ADA-immunoreactive cells were reactive for MAO. Approximately 20% of ADA-immunoreactive neurons represented nearly all cells having 5-HTP uptake capability. However, a very few cells in TM showing 5-HTP uptake capability appeared to be devoid of ADA immunoreactivity. These results demonstrate that although neurons of TM are homogeneous with respect to a number of possible neurotransmitters markers and associated enzymes, these neurons are heterogeneous with respect to their expression of galanin, MAO and 5-HTP uptake. In certain respects the segregation of histochemical properties within TM correlates with previous histochemical work by others, and suggests the possibility of functional diversity of TM.
Brain Res Bull 1986 Sep
PMID:Neuronal colocalization of adenosine deaminase, monoamine oxidase, galanin and 5-hydroxytryptophan uptake in the tuberomammillary nucleus of the rat. 242 41

The present work shows the existence of adenosine-dependent cyclic adenosine monophosphate (AMP) accumulation in the chick optic tectum. When tecta from 18-day-old embryos were incubated with the phosphodiesterase inhibitor IBMX and RO 20-1724, the cyclic AMP level increased from 39.2 to 73.3 and 285.5 pmol/mg protein, respectively. The high level obtained with RO 20-1724 could be inhibited by increasing concentrations of IBMX or by adenosine deaminase, but not by dipyridamole. 2-Chloroadenosine promoted a dose-dependent cyclic AMP accumulation in tecta incubated with RO 20-1724 and adenosine deaminase. This effect was blocked by IBMX and varied substantially during the development of the tissue. The degree of stimulation increased after day 11 of incubation, attaining maximal levels on day 14. The effect of 2-chloroadenosine remained constant until day 18, a period when both the protein content and the basal cyclic AMP levels are increasing in the developing tectum. The cyclic AMP increase elicited by 2-chloroadenosine was greatly reduced in tecta from 20-day-old embryos and 2-day-old chicks. The putative transmitters glutamate and glycine and the neurotransmitter analogs isoproterenol and carbachol had no stimulatory effect on the cyclic AMP accumulation of tecta from 10- and 17-day-old embryos.
Brain Res 1987 Sep
PMID:Development of adenosine-dependent cyclic AMP accumulation in the avian optic tectum. 244 20

It has been found that both adenosine deaminase (ADA) and gamma-interferon (r-IFN) are higher in tuberculous pleural effusions than in other types of pleural effusion. Both mechanisms may be related to the T-lymphocytes in effusions. We studied 39 pleural effusions: 19 tuberculous and 20 malignant [The ADA was determined according to the Giusti method and r-IFN by ELISA]. We compared the ADA and r-IFN levels in both groups of effusions and tried to determine if there was any correlation between them. The results showed: (1) The ADA enzyme level was significantly higher in tuberculous effusions than in malignant effusions as was expected (133.0 +/- 50.4 vs 32.0 +/- 17.7 U/L). (2) The r-IFN was also significantly higher in tuberculous effusions than in malignant effusions (30.4 +/- 17.4 vs 2.9 +/- 2.8 U/ml). (3) The coefficients of regression for the ADA and r-IFN levels were poor. In conclusion, both tests for measuring ADA and r-IFN levels are excellent methods for differentiating tuberculous and malignant effusions, and especially measurement of the r-IFN level could serve as a more specific test for differentiating malignant pleural effusions with high ADA levels. However, no strong correlation was found between the ADA and r-IFN levels.
Taiwan Yi Xue Hui Za Zhi 1989 Sep
PMID:Diagnostic value of adenosine deaminase and gamma-interferon in tuberculous and malignant pleural effusions. 251 12


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>